Heranova Lifesciences

The company's business model revolves around addressing unmet needs in women's healthcare by developing and commercializing a portfolio of diagnostics, therapeutics, and devices, generated through both in-house research and external partnerships. Heranova targets significant gaps in the market, particularly in endometriosis and female infertility. In December 2023, the company secured $13.5 million in a seed and seed+ financing round from institutional investors, including Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital. This capital is allocated to launching a series of non-invasive endometriosis tests and advancing two therapeutic programs for endometriosis and bacterial vaginosis.

Heranova's product pipeline is focused on non-hormonal and non-antibiotic solutions. A key product in development is HerResolve™, a non-invasive, blood-based test for the detection and confirmation of endometriosis, a condition that affects up to 10% of reproductive-age women and often faces diagnostic delays of 8-12 years. The company launched an early access program for HerResolve™ in August 2024 and the LDT-validated version in the U.S. in March 2025. Other pipeline products include HerBiota™, an NGS-based test to assess the uterine microbiome for conditions like chronic endometritis, and HerTempo™, an algorithm-based assessment of ovarian reserve. The company actively seeks collaborations with academic and medical institutions to advance its research and product development.